You are here

lung cancer

First of its Kind “Universal” Immune Cell Cancer Therapy

First of its Kind “Universal” Immune Cell Cancer Therapy

Xtalks

prostate cancer

Cardiff University

Flag link:

BeiGene lung cancer treatment meets main goal in late-stage study

BeiGene lung cancer treatment meets main goal in late-stage study

Reuters

clinical trials

Flag link:

The three biggest challenges in lung cancer, and how researchers are tackling them

The three biggest challenges in lung cancer, and how researchers are tackling them

Pharmaforum

Lung Ambition Alliance

Flag link:

Bankrupt uBiome sells off patents, data for $7M; J&J buys options on Pulmatrix's lung cancer drugs

Bankrupt uBiome sells off patents, data for $7M; J&J buys options on Pulmatrix's lung cancer drugs

Endpoints

Flag link:

Spectrum Pharma Shares Slump After Lung-Cancer Drug Doesn't Meet Phase II Endpoint

Spectrum Pharma Shares Slump After Lung-Cancer Drug Doesn't Meet Phase II Endpoint

TheStreet.com

Spectrum Pharma

clinical trials

non-small cell lung cancer

Flag link:

Upcoming events – Axsome’s depression data and Eli Lilly’s IL-10 in lung cancer

Upcoming events – Axsome’s depression data and Eli Lilly’s IL-10 in lung cancer

EP Vantage

Axsome Therapeutics

treatment-resistant depression

Flag link:

Regeneron defends bid to challenge Merck in lung cancer

Regeneron defends bid to challenge Merck in lung cancer

Biopharma Dive

immuno-oncology

Flag link:

Should Merck Investors Worry About Bristol Myers' Lung Cancer Drug Results?

Should Merck Investors Worry About Bristol Myers' Lung Cancer Drug Results?

Motley Fool

Bristol-Myers Squibb

Flag link:

Triple meeting – Mirati avoids the worst-case scenario

Triple meeting – Mirati avoids the worst-case scenario

EP Vantage

Mirati Therapeutics

colorectal cancer

Flag link:

Lilly touts Cyramza lung cancer data, as AZ’s Tagrisso grows even more powerful

Lilly touts Cyramza lung cancer data, as AZ’s Tagrisso grows even more powerful

Fierce Pharma

EGFR lung cancer

Flag link:

Researchers Develop New Class of Lung Cancer Drugs

Researchers Develop New Class of Lung Cancer Drugs

BioSpace

KRAS inhibitors

Institute of Cancer Research

drug development

Flag link:

Merck KGaA nabs FDA “Breakthrough” tag for MET-targeting lung cancer drug

Merck KGaA nabs FDA “Breakthrough” tag for MET-targeting lung cancer drug

Pharmaforum

non-small cell lung cancer

Flag link:

At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More

At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More

Xconomy

Blueprint Medicines

Flag link:

Rova-T: the story of AbbVie’s multi-billion dollar failure

Rova-T: the story of AbbVie’s multi-billion dollar failure

Pharmaforum

Flag link:

Mylan's Newly-Approved Alimta Generic Will Not be Sold Until 2022

Mylan's Newly-Approved Alimta Generic Will Not be Sold Until 2022

BioSpace

Flag link:

3 Lung Cancer Stocks That Could Soar in September

3 Lung Cancer Stocks That Could Soar in September

Motley Fool

Flag link:

Amgen results beat estimates, lung cancer trial planned

Amgen results beat estimates, lung cancer trial planned

Yahoo/Reuters

clinical trials

Flag link:

AstraZeneca spearheads lung cancer alliance aiming to boost survival rates

AstraZeneca spearheads lung cancer alliance aiming to boost survival rates

Fierce Pharma

Lung Ambition Alliance

Flag link:

Biodesix Looks to Become ‘the’ Lung Cancer Detection Co. With New Acquisition

Biodesix Looks to Become ‘the’ Lung Cancer Detection Co. With New Acquisition

Medical Devices and Diagnostics Industry

Flag link:

Spotlight on: Exosome Diagnostics, first to develop RNA-based liquid biopsies

Spotlight on: Exosome Diagnostics, first to develop RNA-based liquid biopsies

CP Wire

Exosome Diagnostics

prostate cancer

Flag link:

Pages